SOURCE: Generex Biotechnology

June 14, 2007 10:16 ET

Generex Biotechnology Awarded New U.S. Patents for Its Core Vaccine Technologies

WORCESTER, MA--(Marketwire - June 14, 2007) - Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded two new United States patents strengthening its core vaccine technology platform. The first patent, titled Ii-Key/Antigenic Epitope Hybrid Peptide Vaccine, and the second patent, titled Hybrid Peptides Modulate the Immune Response, both help secure the novel Antigen Express vaccine technology platform which is the foundation for a number of vaccine products presently in clinical development.

Proprietary immunotherapeutic cancer vaccines as well as prophylactic vaccines for infectious disease derive increased protection under these patents. The most advanced product is an immunotherapeutic vaccine that has entered Phase II clinical trials in breast cancer patients. The same compound is being tested in a Phase I clinical trial in prostate cancer patients. In addition, other hybrid peptide vaccines, based upon the same technology, are being tested in a Phase I clinical trial for their ability to generate an immune response against the potentially pandemic H5N1 avian influenza virus. To date, these types of epitope hybrid peptide vaccines have been tested in over 115 individuals and appear to be safe and well-tolerated.

The increased activity of peptide vaccines designed using this technology is the result of their ability to potently stimulate CD4+ T helper cells to recognize specific pathogenic agents. T helper cells play a critical role in enabling the immune system to recognize novel agents and establishing immunological 'memory.'

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:
    Shayne Gilliatt
    Generex
    800-391-6755
    416-364-2551

    Andrew Hellman
    CEOcast, Inc.
    212-732-4300